stockportfolio.pro
TG Therapeutics, Inc. (TGTX)
Healthcare · Biotechnology · NasdaqCM
TG Therapeutics, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $152,000 | $152,000 | $152,000 | $152,000 | $152,000 | $6.69M | $2.79M | $233.66M | $329.00M | $616.29M |
| Gross profit | — | — | — | — | — | $5.90M | $2.52M | $219.53M | $290.52M | $515.57M |
| Net income | $-78.25M | $-118.48M | $-173.48M | $-172.87M | $-279.38M | $-348.10M | $-198.34M | $12.67M | $23.38M | $447.18M |
| Net margin | -51482.2% | -77944.7% | -114132.9% | -113730.9% | -183803.3% | -5204.1% | -7121.5% | 5.4% | 7.1% | 72.6% |
Source: TG Therapeutics, Inc. SEC filings (10-K). 15 years of history available in the interactive view.
Explore 15 years of TG Therapeutics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track TGTX in your portfolio →
About TG Therapeutics, Inc.
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
TG Therapeutics, Inc. — frequently asked questions
What is TG Therapeutics, Inc.'s revenue?
TG Therapeutics, Inc. (TGTX) reported revenue of $616.29M for fiscal year 2025, up 87.3% from the prior year, according to its SEC filings.
Is TG Therapeutics, Inc. profitable?
Yes. TGTX earned net income of $447.18M in fiscal 2025, a net margin of 72.6%.
What is TGTX's P/E ratio?
TG Therapeutics, Inc. trades at a price-to-earnings ratio of about 16.3 based on the latest data in our nightly-refreshed cache.
How fast is TG Therapeutics, Inc. growing?
TGTX's revenue grew at roughly 426.7% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
Where does this data come from?
All figures are computed from TG Therapeutics, Inc.'s official SEC filings (10-K and 10-Q), covering 15 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.